Kidney Outcomes in Patients With Advanced Heart Failure Treated With Ventricular Assist Devices

IF 3.2 Q1 UROLOGY & NEPHROLOGY
Lyle W. Baker , Tambi Jarmi , Michael A. Mao , Ivan E. Porter , Christopher L. Trautman , Parag C. Patel , Yaohua Ma , David O. Hodge , Nabeel Aslam
{"title":"Kidney Outcomes in Patients With Advanced Heart Failure Treated With Ventricular Assist Devices","authors":"Lyle W. Baker ,&nbsp;Tambi Jarmi ,&nbsp;Michael A. Mao ,&nbsp;Ivan E. Porter ,&nbsp;Christopher L. Trautman ,&nbsp;Parag C. Patel ,&nbsp;Yaohua Ma ,&nbsp;David O. Hodge ,&nbsp;Nabeel Aslam","doi":"10.1016/j.xkme.2025.101027","DOIUrl":null,"url":null,"abstract":"<div><h3>Rationale &amp; Objective</h3><div>Ventricular assist devices (VADs) are used for advanced heart failure, but their impact on kidney function remains unclear. This study evaluated changes in kidney function following VAD implantation, including acute kidney injury (AKI) incidence and need for kidney replacement therapy (KRT).</div></div><div><h3>Study Design</h3><div>A retrospective cohort study analyzing longitudinal kidney function outcomes post-VAD placement.</div></div><div><h3>Setting &amp; Participants</h3><div>Adult patients who underwent durable VAD placement (2009-2019) at a single center were included. Patients were stratified into chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR]<!--> <!-->&lt;60<!--> <!-->mL/min/1.73m<sup>2</sup>) and non-CKD (eGFR<!--> <!-->≥60<!--> <!-->mL/min/1.73m<sup>2</sup>) groups.</div></div><div><h3>Exposures &amp; Predictors</h3><div>The VAD implantation was the primary intervention, with baseline kidney function modifying its impact on post-VAD kidney function.</div></div><div><h3>Outcomes</h3><div>Primary outcomes were changes in eGFR and creatinine at 3-months and 12-months post-VAD. Secondary outcomes included AKI incidence, KRT requirement, and postdischarge AKI within 1 year.</div></div><div><h3>Analytical Approach</h3><div>Descriptive statistics and comparative analyses, including Wilcoxon rank sum, χ<sup>2</sup>, and paired <em>t</em> tests, were used to assess differences. Significance was set at <em>P</em> <!-->&lt;<!--> <!-->0.05.</div></div><div><h3>Results</h3><div>Among 160 patients (82% male and 69% White), patients with CKD were older with a higher prevalence of diabetes, vasodilator use, and inotrope use. At 3 months, kidney function improved in patients with CKD (eGFR<!--> <!-->+17, <em>P</em> <!-->&lt;<!--> <!-->0.001) but declined by 12 months (eGFR<!--> <!-->+7, <em>P</em> <!-->=<!--> <!-->0.03). The non-CKD group had a smaller improvement at 3 months (eGFR<!--> <!-->+8, <em>P</em> <!-->=<!--> <!-->0.004) that was not sustained. AKI requiring KRT occurred in 14%, with 45% in-hospital mortality; and 41% discontinued KRT before discharge. Post-VAD AKI occurred in 21%. Half of the patients underwent heart transplant, which was associated with worsening kidney function at 1-year.</div></div><div><h3>Limitations</h3><div>Single-center design limits generalizability.</div></div><div><h3>Conclusions</h3><div>The VAD placement initially improves kidney function, particularly in CKD patients, but this effect diminishes over time. AKI and KRT use are common, highlighting the need for close kidney monitoring post-VAD.</div></div><div><h3>Plain-Language Summary</h3><div>Ventricular assist devices (VADs) help patients with advanced heart failure by supporting heart function, but their impact on kidney health is not well understood. Because kidney disease is common in heart failure and linked to worse outcomes, we studied how kidney function changes after VAD placement. We compared patients with and without chronic kidney disease and found that kidney function improved in the first 3 months, especially in those with chronic kidney disease. However, this benefit declined over the first year. Some patients developed acute kidney injury requiring dialysis, which significantly increased their risk of death. These findings highlight the importance of closely monitoring kidney health in VAD patients to improve long-term outcomes.</div></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"7 7","pages":"Article 101027"},"PeriodicalIF":3.2000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590059525000639","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Rationale & Objective

Ventricular assist devices (VADs) are used for advanced heart failure, but their impact on kidney function remains unclear. This study evaluated changes in kidney function following VAD implantation, including acute kidney injury (AKI) incidence and need for kidney replacement therapy (KRT).

Study Design

A retrospective cohort study analyzing longitudinal kidney function outcomes post-VAD placement.

Setting & Participants

Adult patients who underwent durable VAD placement (2009-2019) at a single center were included. Patients were stratified into chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73m2) and non-CKD (eGFR ≥60 mL/min/1.73m2) groups.

Exposures & Predictors

The VAD implantation was the primary intervention, with baseline kidney function modifying its impact on post-VAD kidney function.

Outcomes

Primary outcomes were changes in eGFR and creatinine at 3-months and 12-months post-VAD. Secondary outcomes included AKI incidence, KRT requirement, and postdischarge AKI within 1 year.

Analytical Approach

Descriptive statistics and comparative analyses, including Wilcoxon rank sum, χ2, and paired t tests, were used to assess differences. Significance was set at P < 0.05.

Results

Among 160 patients (82% male and 69% White), patients with CKD were older with a higher prevalence of diabetes, vasodilator use, and inotrope use. At 3 months, kidney function improved in patients with CKD (eGFR +17, P < 0.001) but declined by 12 months (eGFR +7, P = 0.03). The non-CKD group had a smaller improvement at 3 months (eGFR +8, P = 0.004) that was not sustained. AKI requiring KRT occurred in 14%, with 45% in-hospital mortality; and 41% discontinued KRT before discharge. Post-VAD AKI occurred in 21%. Half of the patients underwent heart transplant, which was associated with worsening kidney function at 1-year.

Limitations

Single-center design limits generalizability.

Conclusions

The VAD placement initially improves kidney function, particularly in CKD patients, but this effect diminishes over time. AKI and KRT use are common, highlighting the need for close kidney monitoring post-VAD.

Plain-Language Summary

Ventricular assist devices (VADs) help patients with advanced heart failure by supporting heart function, but their impact on kidney health is not well understood. Because kidney disease is common in heart failure and linked to worse outcomes, we studied how kidney function changes after VAD placement. We compared patients with and without chronic kidney disease and found that kidney function improved in the first 3 months, especially in those with chronic kidney disease. However, this benefit declined over the first year. Some patients developed acute kidney injury requiring dialysis, which significantly increased their risk of death. These findings highlight the importance of closely monitoring kidney health in VAD patients to improve long-term outcomes.
使用心室辅助装置治疗晚期心力衰竭患者的肾脏预后
基本原理及目的心室辅助装置(VADs)用于晚期心力衰竭,但其对肾功能的影响尚不清楚。本研究评估了VAD植入后肾功能的变化,包括急性肾损伤(AKI)发生率和肾脏替代治疗(KRT)的需要。研究设计:一项回顾性队列研究,分析vad放置后的纵向肾功能结果。设置,参与者包括在单一中心接受持久VAD放置(2009-2019)的成年患者。将患者分层分为慢性肾病(CKD)组(估计肾小球滤过率[eGFR]≥60 mL/min/1.73m2)和非CKD组(eGFR≥60 mL/min/1.73m2)。曝光,VAD植入是主要干预措施,基线肾功能改变其对VAD后肾功能的影响。主要结果是vad后3个月和12个月eGFR和肌酐的变化。次要结局包括AKI发生率、KRT要求和1年内的出院后AKI。分析方法采用描述性统计和比较分析,包括Wilcoxon秩和、χ2和配对t检验来评估差异。P <;0.05.结果在160例患者中(82%为男性,69%为白人),CKD患者年龄较大,糖尿病、血管扩张剂和肌力药物的患病率较高。3个月时,CKD患者肾功能改善(eGFR +17, P <;0.001),但12个月后下降(eGFR +7, P = 0.03)。非ckd组在3个月时有较小的改善(eGFR +8, P = 0.004),但没有持续。需要KRT治疗的AKI发生率为14%,住院死亡率为45%;41%在出院前停用KRT。vad后AKI发生率为21%。一半的患者接受了心脏移植,这与1年后肾功能恶化有关。限制单中心设计限制了通用性。结论:VAD的放置最初可以改善肾功能,特别是CKD患者,但这种效果随着时间的推移而减弱。AKI和KRT的使用是常见的,强调了vad后密切监测肾脏的必要性。心室辅助装置(VADs)通过支持心功能来帮助晚期心力衰竭患者,但其对肾脏健康的影响尚不清楚。由于肾脏疾病在心力衰竭中很常见,并且与较差的预后有关,因此我们研究了VAD放置后肾功能的变化。我们比较了有和没有慢性肾脏疾病的患者,发现肾功能在前3个月有所改善,特别是那些有慢性肾脏疾病的患者。然而,这种好处在第一年就下降了。一些患者出现需要透析的急性肾损伤,这大大增加了他们的死亡风险。这些发现强调了密切监测VAD患者肾脏健康对改善长期预后的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Kidney Medicine
Kidney Medicine Medicine-Internal Medicine
CiteScore
4.80
自引率
5.10%
发文量
176
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信